Blueprint Medicines Corp (NAS:BPMC)
$ 101.89 -2.95 (-2.81%) Market Cap: 6.38 Bil Enterprise Value: 6.26 Bil PE Ratio: 0 PB Ratio: 20.54 GF Score: 72/100

Blueprint Medicines Corp Call to Discuss Data Reported at AACR Transcript

Apr 08, 2022 / 06:00PM GMT
Release Date Price: $69.59 (+1.80%)
Operator

Good afternoon. My name is Tania, and I will be your conference operator today. At this time, I would like to welcome everyone to the Blueprint Medicines conference call. (Operator Instructions) Thank you.

Jenna Cohen, you may begin your conference.

Jenna Cohen
Blueprint Medicines Corporation - Senior Director & Head of IR

Thank you, Tania. Good afternoon, everyone and welcome to Blueprint Medicines conference call to discuss the presentation of initial BLU-945 clinical data at the AACR 2022 Annual Meeting. You can access the press release announcing the data, as well as the slides that we'll be reviewing today by going to the Investors and Media section of our website at www.blueprintmedicines.com.

With me on the call today are Kate Haviland, our Chief Executive Officer; Dr. Fouad Namouni, our President of Research and Development and Dr. David Spigel, the Chief Scientific Officer of the Sarah Cannon Research Institute. Dr. Becker Hewes, our Chief Medical Officer

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot